+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Drug Screening Market by Technology, Drug Type, Sample Type, End User - Global Forecast to 2030- Product Image
Drug Screening Market by Technology, Drug Type, Sample Type, End User - Global Forecast to 2030- Product Image
Sale

Drug Screening Market by Technology, Drug Type, Sample Type, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 192 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6083338
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Drug Screening Market grew from USD 9.89 billion in 2024 to USD 11.36 billion in 2025. It is expected to continue growing at a CAGR of 14.49%, reaching USD 22.28 billion by 2030.

Setting the Stage for Tomorrow's Drug Screening Era

The landscape of drug screening has entered a pivotal moment defined by accelerating innovation, tightening regulations, and expanding global demand. As the convergence of analytical sophistication and urgent public health needs intensifies, stakeholders across diagnostics providers, forensic laboratories, and end users find themselves at the threshold of transformative opportunities. This report delivers a foundational overview of the current state of drug screening, tracing its evolution from traditional colorimetric tests to high-resolution mass spectrometry, while framing the competitive dynamics shaping the market today.

Against a backdrop of rising concerns over substance misuse and regulatory scrutiny, decision-makers must balance accuracy, throughput, and cost efficiency in selecting appropriate testing modalities. This introduction outlines the key forces propelling market growth, highlights pressing challenges in supply chain resilience, and underscores the critical role of strategic investments in technology and partnerships. By setting the stage for deeper analysis, it primes readers to navigate complex segmentation, regional variations, and tariff impacts with clarity and confidence.

Emerging Forces Reshaping Drug Screening Practices

Rapid advancements in automation and digital integration are redefining how laboratories approach drug screening. Traditional manual workflows are giving way to streamlined platforms that incorporate robotics, artificial intelligence-driven data interpretation, and cloud-based result management. At the same time, the proliferation of point-of-care testing solutions is extending reach beyond centralized facilities, enabling clinicians to obtain timely results in emergency and outpatient settings.

Concurrently, regulatory agencies worldwide are tightening standards for assay sensitivity and specificity, driving demand for advanced detection technologies that can identify a broader array of substances at lower thresholds. This push toward higher analytical performance coincides with growing interest in multiplexed platforms capable of screening multiple drug classes in a single run. Together, these shifts are accelerating the adoption of mass spectrometry methods and enhanced immunoassays, while encouraging vendors to forge strategic alliances to deliver integrated end-to-end solutions. Transitioning from legacy systems to next-generation instrumentation, the industry is undergoing a metamorphosis that promises to elevate accuracy, expand testing capacity, and unlock new applications in forensic, clinical, and workplace environments.

How 2025 U.S. Tariffs Are Recalibrating the Screening Supply Chain

The introduction of new U.S. tariffs in 2025 has reverberated across the global drug screening supply chain. Laboratory consumables, reagents, and key instrumentation components imported under affected categories have experienced cost inflations that laboratory managers must now absorb or pass on to end users. These increases have prompted many organizations to reassess supplier relationships and explore domestic manufacturing partnerships to mitigate exposure to further trade disruptions.

In response, some forward-looking vendors have diversified their procurement strategies, sourcing critical materials from tariff-exempt regions or negotiating long-term contracts that lock in favorable pricing. Others are accelerating research into alternative assay chemistries that rely on readily available raw materials. Although price adjustments have applied upward pressure on testing fees in certain segments, the competitive landscape remains robust as providers leverage scale and innovation to offset rising input costs. Navigating these tariff-driven headwinds requires agility, strategic procurement planning, and proactive dialogue with policymakers to safeguard continuity of supply and preserve affordability for end users.

Unveiling Patterns Across Technologies, Drugs, Samples, and Users

A nuanced understanding of market segments reveals diverse growth drivers across technologies, analytes, specimen types, and end-user settings. Analysis by technology underscores that chromatography, subdivided into gas chromatography and liquid chromatography, holds a substantial share due to its established workflows and cost-effective instrumentation. Immunoassay approaches, encompassing chemiluminescent immunoassays, enzyme-linked fluorescent assays, and enzyme-linked immunosorbent assays, are prized for rapid turnaround times and ease of automation. At the forefront of sensitivity demands, mass spectrometry techniques such as gas chromatography-mass spectrometry and liquid chromatography-tandem mass spectrometry are gaining traction for their unparalleled specificity.

Disaggregating by drug type shows robust demand for amphetamines and cocaine screening, while opiates-including codeine, heroin, and morphine-remain a primary focus in both clinical and forensic contexts. Phencyclidine and tetrahydrocannabinol continue to feature prominently as regulators and employers tighten testing protocols. Specimen preferences vary by setting, with blood and urine tests dominating clinical laboratories, hair analysis prized for long-term detection, and oral fluids and saliva gaining ground in roadside and workplace scenarios due to noninvasive sampling. Lastly, application across clinical laboratories, drug treatment centers, forensic laboratories, home testing platforms, and workplace testing services highlights the need for tailored solutions that meet distinct operational requirements and regulatory frameworks.

Regional Dynamics Driving Global Drug Screening Strategies

Regional dynamics shape the strategic priorities of market participants as adoption curves and regulatory environments evolve across major territories. In the Americas, well-established infrastructure and high volumes of workplace and clinical testing drive demand for both high-throughput platforms and rapid, point-of-care assays. Stakeholders in this region prioritize scalability and integration with digital health records to streamline reporting and compliance.

Throughout Europe, the Middle East, and Africa, harmonization efforts around substance control and forensic standards are creating new opportunities for consolidated testing hubs. Laboratories are investing in cross-jurisdictional accreditation and deploying multiplexed immunoassay panels to handle diverse case loads. Simultaneously, emerging economies within this zone are adopting innovative mobile testing units to expand access in underserved areas.

Asia-Pacific stands out for its rapid market expansion, fueled by rising healthcare spending, heightened awareness of drug misuse, and an increasing number of accredited forensic facilities. Local manufacturing initiatives are reducing reliance on imports, while growth in home-based screening solutions addresses both urban and rural demand. Across all regions, partnerships between public health agencies and private diagnostics firms are reinforcing the collective response to substance abuse challenges.

Profiles of Industry Leaders Steering Innovation

Industry leaders are distinguishing themselves through differentiated portfolios and strategic collaborations. Established multi-national players leverage broad instrumentation suites spanning chromatography, immunoassay, and mass spectrometry, paired with digital platforms for data management and regulatory compliance. These organizations emphasize continuous innovation in assay development and high-throughput automation to maintain market share and anticipate evolving analytical requirements.

At the same time, specialized technology providers focus on niche applications such as ultra-sensitive detection of emerging psychoactive substances or point-of-care devices optimized for field settings. Several mid-sized firms are forging partnerships with clinical networks and forensic consortia to co-develop integrated testing solutions that combine sample collection, analysis, and reporting within unified workflows. Investment in research and development remains a core strategy, with companies allocating significant resources to bioinformatics, machine learning algorithms, and novel assay chemistries. As competition intensifies, the ability to deliver turnkey services-spanning instrument installation, method validation, and ongoing training-has become a critical differentiator in winning long-term contracts.

Strategic Paths for Market Leadership in Drug Screening

To excel in the evolving drug screening market, organizations should prioritize a multifaceted approach that balances technological leadership with supply chain resilience. Investing in advanced mass spectrometry and multiplexed immunoassay capabilities will meet rising expectations for sensitivity and throughput, while diversifying procurement channels can safeguard against future tariff or geopolitical disruptions. Cultivating partnerships with end users such as clinical laboratories and drug treatment centers will ensure that assay development aligns with real-world operational needs.

Simultaneously, stakeholders must engage with regulatory bodies to contribute to balanced policy frameworks that uphold public safety without stifling innovation. Expanding point-of-care testing initiatives and strengthening digital connectivity between testing sites and healthcare providers will enhance patient outcomes and reporting accuracy. Further, forging alliances across regions can facilitate knowledge transfer and scale economies, reducing cost pressures and accelerating market entry in high-growth territories. By embracing this holistic strategy, industry leaders can not only navigate current challenges but also pioneer the next wave of drug screening excellence.

Methodical Foundations Underpinning Our Analysis

Our analysis draws upon a rigorous blend of primary and secondary research methodologies designed to deliver comprehensive, reliable insights. Primary research consisted of in-depth interviews with senior executives, laboratory directors, and regulatory experts, complemented by direct surveys of end users across clinical, forensic, and workplace testing environments. Secondary research incorporated an extensive review of scientific literature, patent filings, regulatory documents, and company disclosures to validate market trends and competitive positioning.

Quantitative data were triangulated through multiple sources to ensure consistency, while qualitative inputs were synthesized to contextualize emerging technologies and regional dynamics. Market segmentation was structured around technology platforms, drug classes, specimen types, and end-user applications, facilitating granular analysis of growth drivers and barriers. Throughout the research process, rigorous quality control protocols and peer reviews were applied to eliminate bias and maintain analytical integrity. This methodology underpins the strategic recommendations and projections provided in this report, ensuring that decision-makers can proceed with confidence.

Synthesizing Insights for a Forward-Looking Market Approach

The convergence of advanced technologies, shifting regulatory landscapes, and tariff-related supply chain pressures presents both challenges and opportunities for stakeholders in the drug screening market. Through detailed segmentation, regional assessment, and competitor profiling, this executive summary has illuminated the critical factors that will influence market trajectories in the coming years. By synthesizing these insights, organizations are better equipped to make informed decisions on technology investments, partnership strategies, and operational optimizations.

Ultimately, success in this dynamic environment will depend on the agility to adapt to evolving analytical demands, the foresight to anticipate policy shifts, and the determination to collaborate across industry and government. Embracing a forward-looking perspective, one that integrates innovative assay development with resilient sourcing and regional expertise, will be essential to achieving sustainable growth. As the market continues to mature, those who align strategic vision with operational excellence will emerge as the definitive leaders in drug screening solutions.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology
    • Chromatography
      • Gas Chromatography
      • Liquid Chromatography
    • Immunoassay
      • Chemiluminescent Immunoassay
      • Enzyme-Linked Fluorescent Assay
      • Enzyme-Linked Immunosorbent Assay
    • Mass Spectrometry
      • Gas Chromatography Mass Spectrometry
      • Liquid Chromatography-Tandem Mass Spectrometry
  • Drug Type
    • Amphetamines
    • Cocaine
    • Opiates
      • Codeine
      • Heroin
      • Morphine
    • Phencyclidine
    • Tetrahydrocannabinol
  • Sample Type
    • Blood
    • Hair
    • Oral Fluid
    • Saliva
    • Urine
  • End User
    • Clinical Laboratories
    • Drug Treatment Centers
    • Forensic Laboratories
    • Home Testing
    • Workplace Testing
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Roche Holding AG
  • Abbott Laboratories
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • Sysmex Corporation

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Drug Screening Market, by Technology
8.1. Introduction
8.2. Chromatography
8.2.1. Gas Chromatography
8.2.2. Liquid Chromatography
8.3. Immunoassay
8.3.1. Chemiluminescent Immunoassay
8.3.2. Enzyme-Linked Fluorescent Assay
8.3.3. Enzyme-Linked Immunosorbent Assay
8.4. Mass Spectrometry
8.4.1. Gas Chromatography Mass Spectrometry
8.4.2. Liquid Chromatography-Tandem Mass Spectrometry
9. Drug Screening Market, by Drug Type
9.1. Introduction
9.2. Amphetamines
9.3. Cocaine
9.4. Opiates
9.4.1. Codeine
9.4.2. Heroin
9.4.3. Morphine
9.5. Phencyclidine
9.6. Tetrahydrocannabinol
10. Drug Screening Market, by Sample Type
10.1. Introduction
10.2. Blood
10.3. Hair
10.4. Oral Fluid
10.5. Saliva
10.6. Urine
11. Drug Screening Market, by End User
11.1. Introduction
11.2. Clinical Laboratories
11.3. Drug Treatment Centers
11.4. Forensic Laboratories
11.5. Home Testing
11.6. Workplace Testing
12. Americas Drug Screening Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Drug Screening Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Drug Screening Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Quest Diagnostics Incorporated
15.3.2. Laboratory Corporation of America Holdings
15.3.3. Thermo Fisher Scientific Inc.
15.3.4. Roche Holding AG
15.3.5. Abbott Laboratories
15.3.6. Danaher Corporation
15.3.7. Bio-Rad Laboratories, Inc.
15.3.8. Siemens Healthineers AG
15.3.9. Becton, Dickinson and Company
15.3.10. Sysmex Corporation
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. DRUG SCREENING MARKET MULTI-CURRENCY
FIGURE 2. DRUG SCREENING MARKET MULTI-LANGUAGE
FIGURE 3. DRUG SCREENING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DRUG SCREENING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DRUG SCREENING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DRUG SCREENING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DRUG SCREENING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. DRUG SCREENING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DRUG SCREENING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL DRUG SCREENING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL DRUG SCREENING MARKET SIZE, BY CHEMILUMINESCENT IMMUNOASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED FLUORESCENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL DRUG SCREENING MARKET SIZE, BY ENZYME-LINKED IMMUNOSORBENT ASSAY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL DRUG SCREENING MARKET SIZE, BY GAS CHROMATOGRAPHY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL DRUG SCREENING MARKET SIZE, BY LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL DRUG SCREENING MARKET SIZE, BY AMPHETAMINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL DRUG SCREENING MARKET SIZE, BY COCAINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL DRUG SCREENING MARKET SIZE, BY CODEINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL DRUG SCREENING MARKET SIZE, BY HEROIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL DRUG SCREENING MARKET SIZE, BY MORPHINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL DRUG SCREENING MARKET SIZE, BY PHENCYCLIDINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL DRUG SCREENING MARKET SIZE, BY TETRAHYDROCANNABINOL, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL DRUG SCREENING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL DRUG SCREENING MARKET SIZE, BY HAIR, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL DRUG SCREENING MARKET SIZE, BY ORAL FLUID, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL DRUG SCREENING MARKET SIZE, BY SALIVA, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL DRUG SCREENING MARKET SIZE, BY URINE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL DRUG SCREENING MARKET SIZE, BY CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL DRUG SCREENING MARKET SIZE, BY DRUG TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL DRUG SCREENING MARKET SIZE, BY FORENSIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL DRUG SCREENING MARKET SIZE, BY HOME TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL DRUG SCREENING MARKET SIZE, BY WORKPLACE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. AMERICAS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 43. AMERICAS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES DRUG SCREENING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 60. CANADA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 61. CANADA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 62. CANADA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 63. CANADA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 64. CANADA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. CANADA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 66. CANADA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 67. CANADA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. MEXICO DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 69. MEXICO DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 70. MEXICO DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 71. MEXICO DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 72. MEXICO DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. MEXICO DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 74. MEXICO DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 75. MEXICO DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 76. BRAZIL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. ARGENTINA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 90. ARGENTINA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 91. ARGENTINA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 92. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 93. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 94. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 95. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 96. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 97. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 98. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 99. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 100. EUROPE, MIDDLE EAST & AFRICA DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 101. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 102. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 103. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 104. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 105. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 106. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 107. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 108. UNITED KINGDOM DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 109. GERMANY DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 110. GERMANY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 111. GERMANY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 112. GERMANY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 113. GERMANY DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 114. GERMANY DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 115. GERMANY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 116. GERMANY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 117. FRANCE DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 118. FRANCE DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 119. FRANCE DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 120. FRANCE DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 121. FRANCE DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. FRANCE DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 123. FRANCE DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 124. FRANCE DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 127. RUSSIA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 128. RUSSIA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 129. RUSSIA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 130. RUSSIA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 131. RUSSIA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 132. RUSSIA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 133. ITALY DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 134. ITALY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 135. ITALY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 136. ITALY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 137. ITALY DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 138. ITALY DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 139. ITALY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 140. ITALY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 141. SPAIN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 142. SPAIN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 143. SPAIN DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 144. SPAIN DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 145. SPAIN DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. SPAIN DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 147. SPAIN DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 148. SPAIN DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 150. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 151. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 152. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 153. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 154. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 155. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 156. UNITED ARAB EMIRATES DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 157. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 162. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 163. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 164. SAUDI ARABIA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 166. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 167. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 168. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 169. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 170. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 171. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 172. SOUTH AFRICA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 173. DENMARK DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 174. DENMARK DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 175. DENMARK DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 176. DENMARK DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 177. DENMARK DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 178. DENMARK DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 179. DENMARK DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 180. DENMARK DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NETHERLANDS DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 182. NETHERLANDS DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 183. NETHERLANDS DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 184. NETHERLANDS DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 185. NETHERLANDS DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 186. NETHERLANDS DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 187. NETHERLANDS DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 188. NETHERLANDS DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 190. QATAR DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 191. QATAR DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 192. QATAR DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 193. QATAR DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 194. QATAR DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 195. QATAR DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 196. QATAR DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 197. FINLAND DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. FINLAND DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 199. FINLAND DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 200. FINLAND DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 201. FINLAND DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 202. FINLAND DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 203. FINLAND DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 204. FINLAND DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 205. SWEDEN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 206. SWEDEN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 207. SWEDEN DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 208. SWEDEN DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 213. NIGERIA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. NIGERIA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 215. NIGERIA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. EGYPT DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 222. EGYPT DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 223. EGYPT DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 224. EGYPT DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 225. EGYPT DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 226. EGYPT DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 227. EGYPT DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 228. EGYPT DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. TURKEY DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 230. TURKEY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 231. TURKEY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 232. TURKEY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 233. TURKEY DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 234. TURKEY DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 235. TURKEY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 236. TURKEY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ISRAEL DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 238. ISRAEL DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 239. ISRAEL DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 240. ISRAEL DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 241. ISRAEL DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 242. ISRAEL DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 243. ISRAEL DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 244. ISRAEL DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. NORWAY DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 246. NORWAY DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 247. NORWAY DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 248. NORWAY DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 249. NORWAY DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. NORWAY DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 251. NORWAY DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 252. NORWAY DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 253. POLAND DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 254. POLAND DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 255. POLAND DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 256. POLAND DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 257. POLAND DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 258. POLAND DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 259. POLAND DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 260. POLAND DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 261. SWITZERLAND DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 262. SWITZERLAND DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 263. SWITZERLAND DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 264. SWITZERLAND DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 265. SWITZERLAND DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 266. SWITZERLAND DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 267. SWITZERLAND DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 268. SWITZERLAND DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 269. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 271. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 272. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 273. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 274. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 275. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 276. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 277. ASIA-PACIFIC DRUG SCREENING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 278. CHINA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 279. CHINA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 280. CHINA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 281. CHINA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 282. CHINA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 283. CHINA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 284. CHINA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 285. CHINA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 286. INDIA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 287. INDIA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 288. INDIA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 289. INDIA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 290. INDIA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 291. INDIA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 292. INDIA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 293. INDIA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. JAPAN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 295. JAPAN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 296. JAPAN DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 297. JAPAN DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 298. JAPAN DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 299. JAPAN DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 300. JAPAN DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 301. JAPAN DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 302. AUSTRALIA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 303. AUSTRALIA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 304. AUSTRALIA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 305. AUSTRALIA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 306. AUSTRALIA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 307. AUSTRALIA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 308. AUSTRALIA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 309. AUSTRALIA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 310. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 311. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 312. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 313. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 314. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 315. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 316. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 317. SOUTH KOREA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 318. INDONESIA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 319. INDONESIA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 320. INDONESIA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 321. INDONESIA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 322. INDONESIA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 323. INDONESIA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 324. INDONESIA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 325. INDONESIA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 326. THAILAND DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 327. THAILAND DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 328. THAILAND DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 329. THAILAND DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 330. THAILAND DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 331. THAILAND DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 332. THAILAND DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 333. THAILAND DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 334. PHILIPPINES DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 335. PHILIPPINES DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 336. PHILIPPINES DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 337. PHILIPPINES DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 338. PHILIPPINES DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 339. PHILIPPINES DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 340. PHILIPPINES DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 341. PHILIPPINES DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 342. MALAYSIA DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 343. MALAYSIA DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 344. MALAYSIA DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 345. MALAYSIA DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 346. MALAYSIA DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 347. MALAYSIA DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 348. MALAYSIA DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 349. MALAYSIA DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 350. SINGAPORE DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 351. SINGAPORE DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 352. SINGAPORE DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 353. SINGAPORE DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 354. SINGAPORE DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 355. SINGAPORE DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 356. SINGAPORE DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 357. SINGAPORE DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 358. VIETNAM DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 359. VIETNAM DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 360. VIETNAM DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 361. VIETNAM DRUG SCREENING MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 362. VIETNAM DRUG SCREENING MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 363. VIETNAM DRUG SCREENING MARKET SIZE, BY OPIATES, 2018-2030 (USD MILLION)
TABLE 364. VIETNAM DRUG SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 365. VIETNAM DRUG SCREENING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 366. TAIWAN DRUG SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 367. TAIWAN DRUG SCREENING MARKET SIZE, BY CHROMATOGRAPHY, 2018-2030 (USD MILLION)
TABLE 368. TAIWAN DRUG SCREENING MARKET SIZE, BY IMMUNOASSAY, 2018-2030 (USD MILLION)
TABLE 369. TAIWAN DRUG SCREENI

Companies Mentioned

The companies profiled in this Drug Screening market report include:
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • Thermo Fisher Scientific Inc.
  • Roche Holding AG
  • Abbott Laboratories
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Siemens Healthineers AG
  • Becton, Dickinson and Company
  • Sysmex Corporation

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages192
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 11.36 Billion
Forecasted Market Value ( USD ) by 2030 $ 22.28 Billion
Compound Annual Growth Rate14.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Toxicology Drug Screening Market by Test Type, Product Type, Sample Type, Drug Class, Application, End User - Global Forecast to 2030 - Product Image

Toxicology Drug Screening Market by Test Type, Product Type, Sample Type, Drug Class, Application, End User - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global
From
Drug Screening - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030) - Product Image

Drug Screening - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2025 - 2030)

  • Report
  • 160 Pages
  • Global
From
Drug Screening Market Size, Share & Trends Analysis Report by Product Type (Instruments, Rapid Testing Devices), Sample Type (Urine Sample, Breath Sample), End-use, Region, and Segment Forecasts, 2024-2030 - Product Image

Drug Screening Market Size, Share & Trends Analysis Report by Product Type (Instruments, Rapid Testing Devices), Sample Type (Urine Sample, Breath Sample), End-use, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
Drug Screening Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product; Technology; Application; and End-User - Product Image

Drug Screening Market Size and Forecasts 2020-2030: Global and Regional Share, Trends, and Growth Opportunity Analysis by Product; Technology; Application; and End-User

  • Report
  • 112 Pages
  • Global
From
Drug Screening Market Size, Share, Trends and Forecast by Product and Service, Sample Type, End User, and Region, 2025-2033 - Product Image

Drug Screening Market Size, Share, Trends and Forecast by Product and Service, Sample Type, End User, and Region, 2025-2033

  • Report
  • 138 Pages
  • Global
From

About the Drug Screening Market

The Drug Screening market is an important part of the Drug Discovery process. It involves the use of high-throughput screening (HTS) technologies to identify potential drug candidates from a large library of compounds. HTS technologies allow for the rapid screening of thousands of compounds in a short period of time, making it an efficient and cost-effective way to identify potential drug candidates. The Drug Screening market is highly competitive, with a number of companies offering a variety of HTS technologies. Companies in the market include Agilent Technologies, Bio-Rad Laboratories, PerkinElmer, Thermo Fisher Scientific, and Promega Corporation. These companies provide a range of products and services, including automated liquid handling systems, cell-based assays, and high-content imaging systems. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.